Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 18-49 years of age, naive to 23-valent pneumococcal polysaccharide vaccine
详细信息 查看全文
- 作者：K.A. Bryanta ; k0brya01@louisville.edu" class="auth_mail" title="E-mail the corresponding author ; R. Frenckb ; Robert.Frenck@cchmc.org" class="auth_mail" title="E-mail the corresponding author ; A. Gurtmanc ; alejandra.gurtman@pfizer.com" class="auth_mail" title="E-mail the corresponding author ; J. Rubinod ; jrubino@pmg-research.com" class="auth_mail" title="E-mail the corresponding author ; J. Treanore ; John_Treanor@URMC.Rochester.edu" class="auth_mail" title="E-mail the corresponding author ; A. Thompsonc ; allison.thompson@pfizer.com" class="auth_mail" title="E-mail the corresponding author ; T.R. Jonesc ; thomas.r.jones@pfizer.com" class="auth_mail" title="E-mail the corresponding author ; V. Sundaraiyerf ; Vani.Sundaraiyer@inventivhealth.com" class="auth_mail" title="E-mail the corresponding author ; L.M. Baxterg ; Lynne.Baxter@pfizer.com" class="auth_mail" title="E-mail the corresponding author ; W.C. Gruberc ; bill.gruber@pfizer.com" class="auth_mail" title="E-mail the corresponding author ; E.A. Eminih ; emilio.emini@pfizer.com" class="auth_mail" title="E-mail the corresponding author ; D.A. Scottc ; dan.scott@pfizer.com" class="auth_mail" title="E-mail the corresponding author ; B. Schmoele-Thomai ; Beate.Schmoele-Thoma@Pfizer.com" class="auth_mail" title="E-mail the corresponding author
- 关键词：AE ; adverse event ; CAP ; community-acquired pneumonia ; GMFR ; geometric mean fold rise ; GMT ; geometric mean titer ; IPD ; invasive pneumococcal disease ; OPA ; opsonophagocytic activity ; PCV13 ; 13-valent pneumococcal conjugate vaccine ; PPSV23 ; 23-valent pneumococcal polysaccharide vaccine ; SAE ; serious adverse event
- 刊名：Vaccine
- 出版年：2015
- 出版时间：26 October 2015
- 年：2015
- 卷：33
- 期：43
- 页码：5854-5860
- 全文大小：591 K
文摘
- •
PCV13 was immunogenic and well tolerated in adults of all ages.
- •
Functional antibody titers were generally higher in adults 18–49 vs 60–64 years.
- •
Adults 18–29 years had the most robust immune response.
- •
Pain at the injection site was the most common local reaction.